← FDA Drug Approvals (Drugs@FDA)
DAPAGLIFLOZIN
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: GLENMARK GENERICS · Approved 2020-03-20
Drug application
- FDA Application #
ANDA211564- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- DAPAGLIFLOZIN
- Generic name
- Dapagliflozin
- Active ingredients
- DAPAGLIFLOZIN
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- GLENMARK GENERICS
- First approval
- 2020-03-20
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown